


Betahistine

Chemical Properties

CAS No. :	5638-76-6
Formula:	C ₈ H ₁₂ N ₂
Molecular Weight:	136.19
Storage:	Powder: -20°C for 3 years In solvent: -80°C for 1 year <small>Actual storage temperature shall be subject to the COA.</small>



Biological Description

Description	Betahistine (Vasomotal) is a histamine analog and H1 receptor agonist that serves as a vasodilator. It is used in MENIERE DISEASE and in vascular headaches but may exacerbate bronchial asthma and peptic ulcers. Betahistine dihydrochloride is an anti-vertigo drug. It is commonly prescribed for balance disorders or to alleviate vertigo symptoms associated with Ménière's disease.
Targets(IC50)	Histamine Receptor

Solubility Information

Solubility	DMSO: 30 mg/mL (220.28 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (14.69 mM),Sonication is recommended. <i>Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.</i>

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	7.3427 mL	36.7134 mL	73.4268 mL
5 mM	1.4685 mL	7.3427 mL	14.6854 mL
10 mM	0.7343 mL	3.6713 mL	7.3427 mL
50 mM	0.1469 mL	0.7343 mL	1.4685 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Albu S, et al. Treatment of Meniere's disease with intratympanic dexamethazone plus high dosage of betahistine. *Am J Otolaryngol.* 2016 May-Jun;37(3):225-30.

Yi C, et al. Efficacy and acceptability of oxcarbazepine vs. carbamazepine with betahistine mesilate tablets in treating vestibular paroxysmia: a retrospective review. *Postgrad Med.* 2016 Apr 18:1-4.

Barak N, et al. A Randomized, Double-Blind, Placebo-Controlled Pilot Study of Betahistine to Counteract Olanzapine-Associated Weight Gain. *J Clin Psychopharmacol.* 2016 Jun;36(3):253-6. doi: 10.1097/JCP.2020020200200200200489. PubMed PMID: 27028981.

Chen YY, et al. Puerarin and betahistine treatment of vertebrobasilar ischemia vertigo: A meta-analysis of randomized controlled trials. *Exp Ther Med.* 2016 Mar;11(3):1051-1058.

Lian J, et al. Ameliorating antipsychotic-induced weight gain by betahistine: Mechanisms and clinical implications. *Pharmacol Res.* 2016 Apr;106:51-63.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481